# Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.

> **NCT07077616** · EARLY_PHASE1 · RECRUITING · sponsor: **Biogenea Pharmaceuticals Ltd.** · enrollment: 29 (estimated)

## Conditions studied

- Glioma

## Interventions

- **BIOLOGICAL:** Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;

## Key facts

- **NCT ID:** NCT07077616
- **Lead sponsor:** Biogenea Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077616, "Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07077616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*